BUZZ-Lexeo rises as it announces leadership changes
Reuters
Jan 27
BUZZ-Lexeo rises as it announces leadership changes
** Shares of drug developer Lexeo TherapeuticsLXEO.O rise 2% to $7.63 premarket
** Co says it named cardiologist Dr. Narinder Bhalla as chief medical officer
** Co says its research head Dr. Eric Adler will become CEO of Myoventive, which focuses on RNA-based treatments for inherited heart conditions
** CTO José Manuel Otero moves to the chief operating officer's role; co also hires two VPs to lead early- and late-stage cardiology programs - LXEO
** Shares up ~51% in 2025
(Reporting by Sahil Pandey in Bengaluru)
((Sahil.Pandey@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.